Quantum Biopharma (QNTM) Asset Writedowns and Impairment (2020 - 2023)

Quantum Biopharma has disclosed Asset Writedowns and Impairment across 4 years of filings, most recently posting $480096.0 for Q1 2023.

• Asset Writedowns and Impairment for Q1 2023 came in at $480096.0, up 297.96% year-over-year; the trailing twelve-month figure through Dec 2024 was $480096.0 (changed N/A YoY), and the FY2023 annual result was $4.6 million, changed N/A from the prior year.
• Asset Writedowns and Impairment came in at $480096.0 for Q1 2023 at Quantum Biopharma, up from -$97264.0 in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $556556.0 in Q1 2021 to a low of -$294947.0 in Q2 2021.
• The 4-year median for Asset Writedowns and Impairment is $22202.8 (2020), against an average of $70164.4.
• Across the five-year window, Asset Writedowns and Impairment soared 730.36% in 2021 and plunged 143.57% in 2022, its largest moves.
• Quantum Biopharma's Asset Writedowns and Impairment stood at $22202.8 in 2020, then sank by 1428.42% to -$294947.0 in 2021, then soared by 67.02% to -$97264.0 in 2022, then soared by 593.6% to $480096.0 in 2023.
• The last three Asset Writedowns and Impairment figures came in at $480096.0 (Q1 2023), -$97264.0 (Q2 2022), and -$242519.0 (Q1 2022), per Business Quant data.